ESR1 and neoplasm: No predictive biomarkers are clinically available [10], even if pathological and molecular characterization of tumor tissues has identified tumor-intrinsic features (ER, PAM50 and TRAR) [10,11,12] and immune features [13] as predictive of trastuzumab efficacy.